A Cohort Establishment Study of Total Management of Ovarian Cancer

A Cohort Establishment Study of Total Management of Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06018935

Enrollment

500

Registered

2023-08-31

Start date

2024-06-17

Completion date

2025-09-01

Last updated

2024-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer, Tumor of Female Reproductive System

Keywords

Ovarian cancer, Cohort study, Whole-process management

Brief summary

A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Detailed description

1. To investigate the effects of surgery, chemotherapy, maintenance therapy and related factors on the prognosis and quality of life of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer); 2. To study the postoperative recovery of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), perioperative complications, adverse reactions after chemotherapy, adverse reactions during targeted drug maintenance therapy, and explore possible effective preventive measures; 3. The prognostic factors of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) were analyzed; 4. To study the efficacy and safety of PARPi in clinical application in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Interventions

OTHERNo intervention

No intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Yes

Inclusion criteria

1. Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital; 2. Can cooperate with later follow-up.

Exclusion criteria

1. Patients with other malignant tumors or previous history of other malignant tumors; 2. Have cognitive impairment.

Design outcomes

Primary

Measure	Time frame	Description
Progress Freesurvival (PFS)	Average six months after study completion.	The time from the start of treatment until the patient progresses further or dies.
Overall Survival (OS)	Average six months after study completion.	Measure the time from the start of treatment to the time of death.

Secondary

Measure	Time frame	Description
Occurrence of adverse reactions	Average six months after study completion.	All adverse events were recorded.

Countries

China

Contacts

Primary ContactDengfeng Wang, Learned scholar

wonderful_96@163.com15982222707

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026